

08/975982

Search results

Refine Search

Search Results -

Terms	Documents
L4 and polyhedrin and p10	5

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Friday, January 02, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L5</u>	L4 and polyhedrin and p10	5	<u>L5</u>
<u>L4</u>	human\$ near10 (immunoglobulin\$ or antibod\$) near10 insect near5 (cells or cell)	69	<u>L4</u>
<u>L3</u>	L2 and polyhedrin and p10	8	<u>L3</u>
<u>L2</u>	human\$ near10 (immunoglob\$ or antibod\$) near20 baculovir\$	130	<u>L2</u>
<u>L1</u>	human\$ near10 immunoglob\$ near20 baculovir\$	9	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 69 of 69 returned.**

-
- ☐ 1. 20030235557. 16 Sep 02. 25 Dec 03. Compositions and methods for WT1 specific immunotherapy. Gaiger, Alexander, et al. 424/93.2; 435/456 A61K048/00 C12N015/863.
-
- ☐ 2. 20030215458. 30 Oct 02. 20 Nov 03. Compositions and methods for WT1 specific immunotherapy. Gaiger, Alexander, et al. 424/185.1; 435/320.1 435/325 435/69.3 530/350 536/23.5 A61K039/00 C07H021/04 C12P021/02 C12N005/06 C07K014/47.
-
- ☐ 3. 20030207252. 22 Aug 01. 06 Nov 03. VPR function and activity. Weiner, David B., et al. 435/5; 424/93.21 435/455 435/974 435/975 514/12 530/350 530/388.35 530/826 536/23.4 536/23.72 A61K048/00 C12N015/63 A61K038/17 C12Q001/70 A01N063/00 A61K038/00 C07K014/00 C12N015/85 C07H021/04 C07K017/00 C12P021/08 G01N033/564 C07K001/00 C07K016/00 C12N015/87 G01N033/53.
-
- ☐ 4. 20030198622. 12 Jul 02. 23 Oct 03. Compositions and methods for WT1 specific immunotherapy. Gaiger, Alexander, et al. 424/93.2; 424/185.1 435/372 514/44 530/350 A61K048/00 A61K039/00 C07K014/47 C12N005/08.
-
- ☐ 5. 20030190697. 22 Jun 01. 09 Oct 03. Novel co-stimulatory molecules. Punnonen, Juha, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C12P021/02 C12N005/06 C07K014/705 C07H021/04.
-
- ☐ 6. 20030190311. 12 Dec 01. 09 Oct 03. Molecules with extended half-lives, compositions and uses thereof. Dall'Acqua, William, et al. 424/130.1; 530/387.3 A61K039/395 C07K016/44.
-
- ☐ 7. 20030176348. 11 Apr 03. 18 Sep 03. Novel polypeptide, novel DNA and novel antibody. Nabeshima, Youichi, et al. 514/12; 435/184 435/320.1 435/325 435/69.2 536/23.2 A61K038/17 C12P021/02 C12N005/06 C07H021/04 C12N009/99.
-
- ☐ 8. 20030175969. 14 Jan 03. 18 Sep 03. Anti-rhesus d monoclonal antibodies. Beliard, Roland, et al. 435/455; 435/334 530/388.22 C12N005/06 C12N015/85 C07K016/30.
-
- ☐ 9. 20030165875. 20 Mar 02. 04 Sep 03. Novel receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof. Colonna, Marco, et al. 435/6; 435/320.1 435/325 435/69.1 530/350 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K014/705.
-
- ☐ 10. 20030162717. 07 Feb 02. 28 Aug 03. Compositions and methods for promoting lipid mobilization in humans. Schacter, Bernice, et al. 514/13; A61K038/00.
-
- ☐ 11. 20030138881. 20 Dec 01. 24 Jul 03. Novel co-stimulatory molecules. Punnonen, Juha, et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C07K014/705 C12P021/02 C12N005/06 C07H021/04.
-
- ☐ 12. 20030129703. 19 Dec 02. 10 Jul 03. Modified dorsal tissue affecting factor and compositions. Economides, Aris, et al. 435/69.1; 435/320.1 435/325 514/12 530/350 536/23.5 A61K038/17 C07K014/705 C12P021/02 C12N005/06.
-
- ☐ 13. 20030119078. 24 Jan 02. 26 Jun 03. Method of reducing immunogenicity of toxicity of an

antibody of IgG class. Graves, Scott S., et al. 435/7.23; 530/388.15 G01N033/574 C07K016/44.

-
- ☐ 14. 20030118585. 17 Oct 01. 26 Jun 03. Use of protein biomolecular targets in the treatment and visualization of brain tumors. Muller, Sabine, et al. 424/143.1; A61K039/395.
-
- ☐ 15. 20030113322. 18 Dec 02. 19 Jun 03. CDR-H1-derived peptide CB11, pharmaceutical compositions made therefrom and methods of treating disorders in mammals. Bes, Cedric, et al. 424/144.1; 530/388.22 A61K039/395 C07K016/28.
-
- ☐ 16. 20030109680. 21 Nov 01. 12 Jun 03. Antibodies for inhibiting blood coagulation and methods of use thereof. Wong, Hing C., et al. 530/388.15; 530/388.25 C07K016/44.
-
- ☐ 17. 20030099931. 22 Apr 02. 29 May 03. Prophylactic and therapeutic monoclonal antibodies. Hart, Mary Kate. 435/5; 424/159.1 530/388.3 A61K039/42 C12Q001/70 C07K016/08 C12P021/08 C07K016/00.
-
- ☐ 18. 20030099631. 19 Sep 02. 29 May 03. Novel proteins, their production and use. Koji, Yoshimura, et al. 424/94.67; 435/226 435/320.1 435/325 435/69.1 536/23.2 A61K038/46 C07H021/04 C12N009/64 C12P021/02 C12N005/06.
-
- ☐ 19. 20030095971. 30 Oct 01. 22 May 03. Compositions and methods for WT1 specific immunotherapy. Gaiger, Alexander, et al. 424/155.1; 424/93.21 435/183 435/320.1 435/325 435/69.1 536/23.2 A61K048/00 A61K039/395 A61K039/00 C12N009/00 C12P021/02 C12N005/06.
-
- ☐ 20. 20030039635. 16 Apr 02. 27 Feb 03. Compositions and methods for WT1 specific immunotherapy. Gaiger, Alexander, et al. 424/93.2; 435/456 514/44 A61K048/00 C12N015/861 C12N015/86.
-
- ☐ 21. 20030022226. 16 Sep 02. 30 Jan 03. Prophylactic and therapeutic monoclonal antibodies. Hooper, Jay W., et al. 435/6; 424/130.1 424/147.1 424/159.1 424/232.1 435/5 A61K039/42 C12Q001/70 C12Q001/68 A61K039/275 A61K039/285 A61K039/395.
-
- ☐ 22. 20020197677. 08 Mar 02. 26 Dec 02. Antibodies expressed in insect cells. Guttieri, Mary C., et al. 435/69.1; 435/320.1 435/326 435/348 435/456 536/23.53 C12P021/02 C07H021/04 C12N005/06 C12N015/86.
-
- ☐ 23. 20020164349. 04 Oct 01. 07 Nov 02. Compositions and methods of using capsid protein from Flaviviruses and Pestiviruses. Weiner, David B., et al. 424/186.1; 435/5 530/350 530/826 536/23.72 C07K001/00 A61K039/12 C07H021/04 C12Q001/70 C07K017/00 C07K014/00.
-
- ☐ 24. 20020102643. 02 Jul 01. 01 Aug 02. Dorsal tissue affecting factor and compositions. Valenzuela, David M., et al. 435/69.1; 435/320.1 435/325 514/12 530/350 536/23.5 A61K038/17 C07K014/435 C12P021/02 C12N005/06.
-
- ☐ 25. 20020090708. 06 Mar 01. 11 Jul 02. DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6). Lee, Tae Ho, et al. 435/226; 530/351 C12N009/64 C07K014/525.
-
- ☐ 26. 20020009447. 09 Feb 01. 24 Jan 02. Prophylactic and therapeutic monoclonal antibodies. Hooper, Jay W., et al. 424/147.1; 530/388.3 A61K039/42 C07K016/00 C12P021/08.
-
- ☐ 27. 6639057. 26 Nov 99; 28 Oct 03. Monoclonal antibody against human telomerase catalytic

subunit. Hanai; Nobuo, et al. 530/388.26; 424/141.1 424/142.1 424/146.1 435/325 435/338 530/387.3 530/388.1 530/388.15. C07K016/00.

☐ 28. 6630144. 29 Aug 00; 07 Oct 03. Monoclonal antibodies to Ebola glycoprotein. Hart; Mary K., et al. 424/159.1; 424/130.1 424/131.1 424/139.1 424/141.1 424/184.1 424/186.1. A61K039/42 A61K039/395.

☐ 29. 6620412. 16 Sep 02; 16 Sep 03. Prophylactic and therapeutic monoclonal antibodies. Hooper; Jay W., et al. 424/147.1; 424/232.1 530/388.3. A61K039/42 A61K039/275.

☐ 30. 6579850. 25 Jun 99; 17 Jun 03. Polypeptide, novel DNA and novel antibody. Nabeshima; Youichi, et al. 514/12; 424/94.61 530/350 930/240. A61K038/16 A61K038/43 C07K014/46.

☐ 31. 6566116. 26 Jul 99; 20 May 03. Matrix metalloprotease. Koji; Yoshimura, et al. 435/226; 435/23 435/252.3 435/320.1 435/69.1 514/2 536/23.2. C12N009/64 C12N015/57 C12Q001/37 A61Q038/48.

☐ 32. 6548061. 28 Oct 98; 15 Apr 03. Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration. Steeves; John D., et al. 424/130.1; 424/141.1 424/172.1. A61K039/395.

☐ 33. 6518401. 06 Mar 01; 11 Feb 03. Tumor necrosis factor stimulated gene 6 (TSG-6) protein. Lee; Tae Ho, et al. 530/350; 530/300 530/351 530/402. C07K014/435 C07K014/475.

☐ 34. 6500640. 08 Feb 00; 31 Dec 02. Nucleic acid molecules encoding modified dorsal tissue affecting factor. Economides; Aris, et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 435/455 536/23.1 536/23.5. C12N001/21 C12N005/16 C12N015/12 C12N015/63.

☐ 35. 6475763. 19 Jan 00; 05 Nov 02. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same. Ayal-HersHKovitz; Maty, et al. 435/200; 435/183 435/23 435/4 435/7.91. C12Q001/00 C12Q001/37 G01N033/53 C12N009/00 C12N009/24.

☐ 36. 6451309. 09 Feb 01; 17 Sep 02. Prophylactic and therapeutic monoclonal antibodies. Hooper; Jay W., et al. 424/147.1; 424/232.1 530/388.3. A61K039/42 A61K039/275.

☐ 37. 6395274. 19 Oct 99; 28 May 02. Monoclonal antibodies specific for human interleukin-5. Huston; David P., et al. 424/145.1; 424/133.1 424/152.1 424/153.1 424/158.1 424/172.1 424/173.1 530/388.23. A61K039/395 C07K016/24.

☐ 38. 6361954. 30 Oct 98; 26 Mar 02. Methods of immunoassay for human CDC6. Stillman; Bruce, et al. 435/7.1; 424/1.49 424/139.1 424/152.1 424/172.1 424/178.1 435/7.23 435/7.9 436/504 436/536 530/387.9 530/391.3. G01N033/53 G01N033/574 G01N033/58 G01N033/60 G01N033/567.

☐ 39. 6358710. 09 Jun 97; 19 Mar 02. Humanized antibodies that bind to the antigen bound by antibody NR-LU-13. Graves; Scott S., et al. 435/70.1; 424/130.1 435/325 435/330 436/547 530/387.1. C12P021/04.

☐ 40. 6348344. 02 Mar 99; 19 Feb 02. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same. Ayal-HersHKovitz; Maty, et al. 435/209; 435/183 435/195 435/200 435/252.33 435/254.2 435/254.21 435/254.23 435/320.1 435/325 435/348 435/354 435/355 435/356 435/357 435/358 435/365 435/366 435/367 435/368 435/369 435/370

435/371 435/372 435/372.1 435/372.2 435/372.3. C12N009/42 C12N009/24 C12N009/00 C12N001/20 C12N015/00.

☐ 41. 6315998. 15 Feb 00; 13 Nov 01. Methods of blocking B-cell activation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.

☐ 42. 6313091. 20 May 98; 06 Nov 01. Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method. Wisniewski; Hans-Georg, et al. 514/12; 435/252.3 435/320.1 435/69.1 514/2 530/350 530/351 530/395 536/23.1. A61K038/00 C07K014/00 C07H021/02 A01N037/18 C12P021/06.

☐ 43. 6312690. 01 Jul 97; 06 Nov 01. Monoclonal recombinant anti-rhesus D (D7C2) antibody. Edelman; Lena, et al. 424/142.1; 424/133.1 424/135.1 424/143.1 424/152.1 424/800 424/801 435/320.1 435/326 435/328 435/334 435/348 530/387.1 530/387.3 530/388.15 530/388.22 530/866 530/867. A61K039/395 C07K016/28 C07H021/04 C12N005/10.

☐ 44. 6277593. 07 Oct 98; 21 Aug 01. Dorsal tissue affecting factor and compositions. Valenzuela; David M., et al. 435/69.1; 435/69.4 530/350 530/399 536/23.5 536/23.51. C12P021/02 C07H021/04 C07K014/435.

☐ 45. 6268484. 30 Jul 98; 31 Jul 01. HIV-vaccines. Katinger; Hermann, et al. 530/388.35; 424/192.1 424/208.1 435/339.1 435/5 435/7.1. C07K016/00 A61K039/00 A61K039/21 C12Q001/70 G01N033/53.

☐ 46. 6210905. 07 Dec 98; 03 Apr 01. Tumor necrosis factor stimulated gene 6 (TSG-6) binding molecules. Lee; Tae Ho, et al. 435/7.1; 436/501 530/387.1 530/388.1. G01N033/53 C07K016/18.

☐ 47. 6075007. 17 Jul 97; 13 Jun 00. Modified noggin polypeptide and compositions. Economides; Aris, et al. 514/12; 530/397 530/399. A61K038/16 C07K014/00.

☐ 48. 6063905. 07 Jan 97; 16 May 00. Recombinant human IGA-J. chain dimer. Capra; J. Donald, et al. 530/387.3; 424/130.1 424/133.1 435/328 530/387.1 530/390.1. C12P021/08 C07K016/00 A61K039/395 C12N005/06.

☐ 49. 6056959. 05 Jun 95; 02 May 00. CD40 antigen antibody complex. de Boer; Mark, et al. 424/178.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1 424/184.1 530/350 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.73. A61K039/395 A61K035/28 C07K016/28 C07K014/435.

☐ 50. 6040149. 10 Jan 97; 21 Mar 00. Assay for identifying agents which act on the ceramide-activated protein kinase, kinase suppressor of ras, and methods of using said agents. Kolesnick; Richard N., et al. 435/15; 424/94.5 435/194. C12Q001/48 C12N009/12 A61K038/51.

☐ 51. 6004552. 05 Jun 95; 21 Dec 99. Methods of blocking B cell proliferation using anti-CD40 monoclonal antibodies. de Boer; Mark, et al. 424/144.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/153.1 424/173.1. A61K039/395.

☐ 52. 5976821. 24 Oct 95; 02 Nov 99. Monoclonal antibodies specific for human interleukin-5. Huston; David P., et al. 435/7.94; 435/335 435/7.92 435/70.21 436/512 436/518 436/536 436/548

530/388.23. G01N033/543 G01N033/577 C07K016/24 C12P021/08.

-
- ☐ 53. 5925362. 10 Aug 94; 20 Jul 99. Method to elicit an antitumor response with human prostate-specific antigen. Spitler; Lynn E., et al. 424/277.1; 424/184.1 424/450 424/520 424/559 424/812 424/93.2 514/44. A61K035/48 A61K048/00.
-
- ☐ 54. 5911989. 07 Jun 95; 15 Jun 99. HIV-vaccines. Katinger; Hermann, et al. 424/160.1; 424/208.1 435/5 530/388.35. A61K039/42 A61K039/21 C12Q001/70 C07K016/00.
-
- ☐ 55. 5874082. 23 Feb 96; 23 Feb 99. Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation. de Boer; Mark. 424/153.1; 424/130.1 424/133.1 424/141.1 424/143.1 424/144.1 424/173.1 530/387.3 530/388.22 530/388.7 530/388.73. A61K039/395 C07K016/28.
-
- ☐ 56. 5869050. 09 Feb 93; 09 Feb 99. Methods of blocking T-cell activation using anti-B7 monoclonal antibodies. de Boer; Mark, et al. 424/156.1; 424/133.1 424/137.1 424/141.1 530/387.1 530/387.5 530/388.1 530/388.85. A61K039/395 C07K016/00.
-
- ☐ 57. 5866787. 07 Jun 95; 02 Feb 99. Transgenic plants co-expressing a functional human 2-5A system. Silverman; Robert H., et al. 800/301; 435/320.1 435/418 435/419 435/69.1 536/23.2 536/23.5 800/317.3. A01H005/00 C12N005/04 C12N015/82.
-
- ☐ 58. 5858723. 05 Dec 95; 12 Jan 99. Polypeptides and antibodies for diagnosing and treating seminoma. Mueller-Lantzsch; Nikolaus, et al. 435/69.3; 530/387.3. C12P021/06 C12P021/08.
-
- ☐ 59. 5846763. 13 May 94; 08 Dec 98. DNA encoding tumor necrosis factor stimulated gene 6 (TSG-6). Lee; Tae Ho, et al. 435/69.1; 435/252.3 435/320.1 536/23.1 536/23.5. C12N005/10 C12N015/12 C12N001/21.
-
- ☐ 60. 5843775. 22 Sep 95; 01 Dec 98. Human dorsal tissue affecting factor (noggin) and nucleic acids encoding same. Valenzuela; David M., et al. 435/325; 435/252.3 435/254.11 435/320.1 435/348 435/69.1 514/12 514/2 514/8 530/350 536/23.1 536/23.5 536/24.1 536/24.31 536/24.33. C07K014/435 C07K014/475 C12N005/10 C12N015/12.
-
- ☐ 61. 5843712. 06 Jun 96; 01 Dec 98. Sindbis virus expression system for recombinant antibody production. Levine; Beth Cindy. 435/69.1; 435/235.1 435/326 435/348 435/456 435/465 435/69.6 435/70.1. C12P021/06 C12P021/04 C12N015/00 C12N007/00.
-
- ☐ 62. 5821124. 07 Jun 95; 13 Oct 98. Hybridoma cell lines and antibodies that bind noggin. Valenzuela; David M., et al. 435/331; 530/387.9 530/388.24 530/388.85. C07K016/22 C12N005/12.
-
- ☐ 63. 5821087. 11 Sep 96; 13 Oct 98. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA. Lowe; Robert, et al. 435/69.3; 424/130.1 424/186.1 424/204.1 435/235.1 435/254.2 435/5 536/23.72. C12Q001/70 C12P021/06 A61K039/21 A61K039/12.
-
- ☐ 64. 5747034. 18 Feb 94; 05 May 98. Methods and materials for the induction of T cell anergy. de Boer; Mark, et al. 424/137.1; 424/141.1 424/156.1 435/329 435/343.1 435/343.2 435/70.21 530/387.1 530/387.3 530/387.5 530/388.1 530/388.85 530/809. A61K039/395 C12N005/12 C12P021/08 C07K016/18.
-
- ☐ 65. 5583031. 06 Feb 92; 10 Dec 96. Empty major histocompatibility class II heterodimers. Stern;

Lawrence J.. 435/69.1; 424/184.1 424/185.1 424/193.1 435/320.1 435/348 435/69.3 514/8 530/395 530/403 530/868. C12N005/06 C12N005/10 C07K014/74.

☐ 66. 5445956. 13 Aug 93; 29 Aug 95. Recombinant soluble epoxide hydrolase. Hammock; Bruce D., et al. 435/195; 435/252.33 435/255.1 435/320.1 536/23.2. C12N009/14 C12N015/55.

☐ 67. 5397703. 09 Jul 92; 14 Mar 95. Method for generation of antibodies to cell surface molecules. De Boer; Mark, et al. 424/93.21; 435/451 435/452 435/456 435/467 435/6 530/389.1. C12N015/02 C12N015/06 A61K039/00.

☐ 68. WO 200292812A. Artificial human chromosome containing human antibody lamda light chain gene transferred to offspring via non-human genital system for constructing transchromosomic mice, applicable in developing human antibody drugs. ISHIDA, I, et al. A01K067/027 C07K016/00 C12N015/09 C12P021/08.

☐ 69. CN 1318565A. Humanized hepatitis A virus neutralizing genetically engineered total antibody. CAO, J, et al. A61K039/395 A61P001/16 A61P031/12 C07K016/18 C07K016/44.

Generate Collection

Print

Terms	Documents
human\$ near10 (immunoglobulin\$ or antibod\$) near10 insect near5 (cells or cell)	69

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)



Day : Friday
Date: 1/2/2004
Time: 13:48:05

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday
Date: 1/2/2004
Time: 13:48:05

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)